» Articles » PMID: 26868960

Normal Weight Dyslipidemia: Is It All About the Liver?

Overview
Date 2016 Feb 13
PMID 26868960
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The liver coordinates lipid metabolism and may play a vital role in the development of dyslipidemia, even in the absence of obesity. Normal weight dyslipidemia (NWD) and patients with nonalcoholic fatty liver disease (NAFLD) who do not have obesity constitute a unique subset of individuals characterized by dyslipidemia and metabolic deterioration. This review examined the available literature on the role of the liver in dyslipidemia and the metabolic characteristics of patients with NAFLD who do not have obesity.

Methods: PubMed was searched using the following keywords: nonobese, dyslipidemia, NAFLD, NWD, liver, and metabolically obese/unhealthy normal weight. Additionally, article bibliographies were screened, and relevant citations were retrieved. Studies were excluded if they had not measured relevant biomarkers of dyslipidemia.

Results: NWD and NAFLD without obesity share a similar abnormal metabolic profile. When compared with patients with NAFLD who have obesity, the metabolic abnormalities of NAFLD without obesity are similar or less severe. Furthermore, hepatic lesions develop independent of obesity, and the extent of dyslipidemia seems comparable.

Conclusions: NAFLD may impair hepatic lipid handling, causing faulty lipid homeostasis, and serves as a likely starting point for initiation and propagation of dyslipidemia along with associated comorbidities in patients without obesity.

Citing Articles

A high-fat plus high-sucrose diet induces age-related macular degeneration in an experimental rabbit model.

Wang Y, Lv Z, Chen Y, Cen X, Zhang H, Chen D Dis Model Mech. 2024; 17(11).

PMID: 39463155 PMC: 11625886. DOI: 10.1242/dmm.052015.


Analyzing and evaluating the prevalence and metabolic profile of lean NAFLD compared to obese NAFLD: a systemic review and meta-analysis.

Fatima H, Rangwala H, Mustafa M, Shafique M, Abbas S, Rangwala B Ther Adv Endocrinol Metab. 2024; 15:20420188241274310.

PMID: 39234426 PMC: 11372778. DOI: 10.1177/20420188241274310.


Research on the mechanism of sea buckthorn leaf Fu tea in the treatment of hyperlipidemia.

Chen S, Wei W, Huang F, Wang J, Li X, Yang Y Heliyon. 2024; 10(12):e32343.

PMID: 38984297 PMC: 11231531. DOI: 10.1016/j.heliyon.2024.e32343.


Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review.

Sandoval C, Reyes C, Rosas P, Godoy K, Souza-Mello V, Farias J Int J Mol Sci. 2023; 24(21).

PMID: 37958712 PMC: 10648767. DOI: 10.3390/ijms242115728.


Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.

Ding Y, Deng Q, Yang M, Niu H, Wang Z, Xia S Diabetes Metab Syndr Obes. 2023; 16:3303-3329.

PMID: 37905232 PMC: 10613411. DOI: 10.2147/DMSO.S431251.